Cited by 701Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchCholinesterase and Neurodegenerative Diseases

The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.

Alzheimer's disease drug development pipeline: 2018

Open access

Cummings, Jeffrey, Lee, Garam, Ritter, Aaron, Zhong, Kate·2018·Alzheimer's & Dementia: Translational Research & Clinical Interventions

DOI 10.1016/j.trci.2018.03.009PMC PMC6021548

Open this paper in CoChat — free account Open PDF

Abstract

Introduction: Treatments for Alzheimer's disease (AD) are needed due to the growing number of individuals with preclinical, prodromal, and dementia forms of AD. Drug development for AD therapies can be examined by inspecting the drug development pipeline as represented on clinicaltrials.gov . Methods: Clinicaltrials.gov was assessed as of January 30, 2018 to determine AD therapies represented in phase I, phase II, and phase III. Results: There are 112 agents in the current AD treatment pipeline. There are 26 agents in 35 trials in phase III, 63 agents in 75 trials in phase II, and 23 agents in 25 trials in phase I. A review of the mechanisms of actions of the agents in the pipeline shows that 63% are disease‐modifying therapies, 22% are symptomatic cognitive enhancers, and 12% are symptomatic agents addressing neuropsychiatric and behavioral changes. Trials in phase III are larger and longer than phase II or phase I trials, particularly those involving disease‐modifying agents. Comparison with the 2017 pipeline shows that there are four new agents in phase III, 14 in phase II, and eight in phase I. Inspection of the use of biomarkers as revealed on clinicaltrials.gov shows that amyloid biomarkers are used as entry criterion in 14 phase III disease‐modifying agent trials and 17 disease‐modifying agent trials in phase II. Twenty‐one trials of disease‐modifying agents in phase II did not require biomarker confirmation for AD at trial entry. Discussion: The AD drug development pipeline is slightly larger in 2018 than in 2017. Trials increasingly include preclinical and prodromal populations. There is an increase in nonamyloid mechanisms of action for drugs in earlier phases of drug development. Biomarkers are increasingly used in AD drug development but are not used uniformly for AD diagnosis confirmation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.trci.2018.03.009

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging‐Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
Albert, M. S., DeKosky, S. T., Dickson, D., Dubois, B., Feldman, H. H., Fox, N. C., Gamst, A., Holtzman, D. M., Jagust, W. J., Petersen, R. C., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.008 · Cited by 10,152
Forecasting the global burden of Alzheimer's disease
Brookmeyer, R., Johnson, E., Ziegler‐Graham, K., & Arrighi, H. M. (2007) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2007.04.381 · Cited by 3,370
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citation
Alzheimer’s Disease
Scheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Alzheimer's disease
Masters, C. L., Bateman, R., Blennow, K., Rowe, C. C., Sperling, R. A., & Cummings, J. L. (2015) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2015.56 · Cited by 1,853
Self-citation
Alzheimer’s disease drug-development pipeline: Few candidates, frequent failures
Cummings, J. L., Morstorf, T., & Zhong, K. (2014) · Alzheimer's Research & Therapy · doi:10.1186/alzrt269 · Cited by 1,744
Self-citation
Epidemiology of Alzheimer disease
Reitz, C., Brayne, C., & Mayeux, R. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.2 · Cited by 1,675
Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Doody, R. S., Thomas, R. G., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., Raman, R., Sun, X., Aisen, P. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1312889 · Cited by 1,668
Clinical Trial Registration: A Statement from the International Committee of Medical Journal Editors
De Angelis, C., Drazen, J. M., Frizelle, F. A., Haug, C., Hoey, J., Horton, R., Kotzin, S., Laine, C., Marusic, A., Overbeke, A. J. P. M., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejme048225 · Cited by 1,241

Flagged first, then by citations

Show all 48 references

Research works printed but not linked: 1

Lombardo I., 2017, Results from the phase 3 MINDSET STUDY: a global, double‐blind, placebo‐controlled study of intepirdine in mild‐to‐moderate Alzheimer's disease

Sorted by citations

Items 101–200 of 701

Oxidative stress–mediated neuroinflammation in Alzheimer’s disease
Firdous, S. M., Khan, S. A., & Maity, A. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03188-3 · Cited by 90
Natural products and their derivatives as multifunctional ligands against Alzheimer's disease
Patil, P., Thakur, A., Sharma, A., & Flora, S. J. S. (2019) · Drug Development Research · doi:10.1002/ddr.21587 · Cited by 80
FDA position statement “Early Alzheimer's disease: Developing drugs for treatment, Guidance for Industry”
Sabbagh, M. N., Hendrix, S. B., & Harrison, J. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.11.004 · Cited by 80
New insight into Alzheimer's disease: Light reverses Aβ‐obstructed interstitial fluid flow and ameliorates memory decline in APP/PS1 mice
Yue, X., Mei, Y., Zhang, Y., Tong, Z., Cui, D., Wang, A., Wang, R., Wang, R., Fei, X., Di, Y., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.007 · Cited by 79
Bacterial DNA promotes Tau aggregation
Tetz, G. V., Pinho, M. A., Pritzkow, S., Méndez, N., Soto, C. A., & Tetz, V. (2020) · Scientific Reports · doi:10.1038/s41598-020-59364-x · Cited by 81
Antisense oligonucleotides for Alzheimer's disease therapy: from the mRNA to miRNA paradigm
Grabowska, W., Want, A., Leszek, J., & Wojda, U. (2021) · EBioMedicine · doi:10.1016/j.ebiom.2021.103691 · Cited by 81
Preventing and Treating Neurological Disorders with the Flavonol Fisetin
Maher, P. A. (2020) · Brain Plasticity · doi:10.3233/bpl-200104 · Cited by 81
Formaldehyde toxicity in age-related neurological dementia
Kou, Y., Zhao, H., Cui, D., Han, H., & Tong, Z. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101512 · Cited by 82
Polyherbal drug loaded starch nanoparticles as promising drug delivery system: Antimicrobial, antibiofilm and neuroprotective studies
Nallasamy, P., Thenmozhi, R., Thajuddin, N., Shanmuganathan, R., Pugazhendhi, A., & Suganthy, N. (2020) · Process Biochemistry · doi:10.1016/j.procbio.2020.01.026 · Cited by 78
Repurposed agents in the Alzheimer’s disease drug development pipeline
Bauzon, J., Lee, G., & Cummings, J. (2020) · Alzheimer's Research & Therapy · doi:10.1186/s13195-020-00662-x · Cited by 77
Self-citation
All (animal) models (of neurodegeneration) are wrong. Are they also useful?
Ransohoff, R. M. (2018) · The Journal of Experimental Medicine · doi:10.1084/jem.20182042 · Cited by 83
Pharmacological doses of melatonin impede cognitive decline in tau‐related Alzheimer models, once tauopathy is initiated, by restoring the autophagic flux
Luengo, E., Buendía, I., Fernández‐Mendívil, C., Trigo-Alonso, P., Negredo, P., Michalska, P., Hernández-García, B. J., Sánchez‐Ramos, C., Bernal, J. A., Ikezu, T., et al. (2019) · Journal of Pineal Research · doi:10.1111/jpi.12578 · Cited by 76
Fecal Microbiota Transplantation Reduces Pathology and Improves Cognition in a Mouse Model of Alzheimer’s Disease
Elangovan, S., Borody, T. J., & Holsinger, R. M. D. (2022) · Cells · doi:10.3390/cells12010119 · Cited by 87
Elevated levels of Secreted-Frizzled-Related-Protein 1 contribute to Alzheimer’s disease pathogenesis
Esteve, P., Rueda‐Carrasco, J., Mateo, M. I., Martín‐Bermejo, M. J., Draffin, J. E., Pereyra, G., Sandonís, Á., Crespo, I., Moreno, I., Aso, E., et al. (2019) · Nature Neuroscience · doi:10.1038/s41593-019-0432-1 · Cited by 79
Neurodegeneration in type 2 diabetes: Alzheimer's as a case study
Madhusudhanan, J., Suresh, G., & Devanathan, V. (2020) · Brain and Behavior · doi:10.1002/brb3.1577 · Cited by 82
Polyphenol-rich Boswellia serrata gum prevents cognitive impairment and insulin resistance of diabetic rats through inhibition of GSK3β activity, oxidative stress and pro-inflammatory cytokines
Gomaa, A. A., Makboul, R. M., Al-Mokhtar, M. A., & Nicola, M. A. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.10.056 · Cited by 75
The endless frontier? The recent increase of R&D productivity in pharmaceuticals
Pammolli, F., Righetto, L., Abrignani, S., Pani, L., Pelicci, P. G., & Rabosio, E. (2020) · Journal of Translational Medicine · doi:10.1186/s12967-020-02313-z · Cited by 77
Prediction of Alzheimer's disease dementia with MRI beyond the short-term: Implications for the design of predictive models
Moscoso, A., Silva‐Rodríguez, J., Aldrey, J. M., Cortés, J., Fernández‐Ferreiro, A., Gómez‐Lado, N., Ruibal, Á., & Aguiar, P. (2019) · NeuroImage Clinical · doi:10.1016/j.nicl.2019.101837 · Cited by 74
Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay
Shi, L., Westwood, S., Baird, A. L., Winchester, L. M., Dobričić, V., Kilpert, F., Hong, S., Franke, A., Hye, A., Ashton, N. J., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4951 · Cited by 70
Therapeutic potential of quinazoline derivatives for Alzheimer's disease: A comprehensive review
Haghighijoo, Z., Zamani, L., Moosavi, F., & Emami, S. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113949 · Cited by 77
Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice
Ettcheto, M., Cano, A., Manzine, P. R., Busquets, O., Verdaguer, E., Castro-Torres, R. D., García, M. L., Beas-Zarate, C., Olloquequi, J., Auladell, C., et al. (2020) · Molecular Neurobiology · doi:10.1007/s12035-019-01849-6 · Cited by 73
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease
Melchior, B., Mittapalli, G. K., Lai, C., Duong‐Polk, K., Stewart, J., Güner, B., Hofilena, B. J., Tjitro, A., Anderson, S., Herman, D. S., et al. (2019) · Aging Cell · doi:10.1111/acel.13000 · Cited by 73
Behavioral and neural network abnormalities in human APP transgenic mice resemble those of App knock-in mice and are modulated by familial Alzheimer's disease mutations but not by inhibition of BACE1
Johnson, E. C. B., Ho, K., Yu, G.-Q., Das, M., Sanchez, P. E., Djukic, B., Lopez, I., Yu, X., Gill, M., Zhang, W., et al. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00393-5 · Cited by 73
Predicting sporadic Alzheimer's disease progression via inherited Alzheimer's disease‐informed machine‐learning
Franzmeier, N., Koutsouleris, N., Benzinger, T. L. S., Goate, A., Karch, C. M. M., Fagan, A. M., McDade, E., Duering, M., Dichgans, M., Levin, J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12032 · Cited by 76
Anti-Tau Trials for Alzheimer's Disease: A Report from the EU/US/CTAD Task Force
Cummings, J. L., Blennow, K., Johnson, K. A., Keeley, M. B., Bateman, R. J., Molinuevo, J. L., Touchon, J., Aisen, P. S. S., & Vellas, B. J. (2019) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2019.14 · Cited by 72
Self-citation
Plasma proteins, cognitive decline, and 20-year risk of dementia in the Whitehall II and Atherosclerosis Risk in Communities studies
Lindbohm, J. V., Mars, N., Walker, K. A., Singh‐Manoux, A., Livingston, G., Brunner, E. J., Sipilä, P. N., Saksela, K., Ferrie, J. E., Lovering, R. C., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12419 · Cited by 70
Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies
Lo, C. H., Lim, C. K., Ding, Z., Wickramasinghe, S. P., Braun, A. R., Ashe, K. H., Rhoades, E. R., Thomas, D. D., & Sachs, J. N. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.06.4954 · Cited by 65
Ketogenic Diet for the Treatment and Prevention of Dementia: A Review
Davis, J. J., Fournakis, N. A., & Ellison, J. M. (2020) · Journal of Geriatric Psychiatry and Neurology · doi:10.1177/0891988720901785 · Cited by 73
Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study
Alves, I. L., Collij, L. E., Altomare, D., Frisoni, G. B., Saint‐Aubert, L., Payoux, P., Kivipelto, M., Jessen, F., Drzezga, A. E., Leeuwis, A. E., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12069 · Cited by 67
The Involvement of Peripheral and Brain Insulin Resistance in Late Onset Alzheimer’s Dementia
Folch, J., Olloquequi, J., Ettcheto, M., Busquets, O., Sánchez‐López, E., Cano, A. C., Espinosa-Jiménez, T., García, M. L., Beas‐Zárate, C., Casadesús, G., et al. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00236 · Cited by 70
Targeting Tau Hyperphosphorylation via Kinase Inhibition: Strategy to Address Alzheimer's Disease
Naqvi, A. A. T., Hasan, G. M., & Hassan, M. I. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620666200106125910 · Cited by 70
ApoA-I deficiency increases cortical amyloid deposition, cerebral amyloid angiopathy, cortical and hippocampal astrogliosis, and amyloid-associated astrocyte reactivity in APP/PS1 mice
Button, E. B., Boyce, G. K., Wilkinson, A., Stukas, S. K., Hayat, A., Fan, J., Wadsworth, B. J., Robert, J., Martens, K. M., & Wellington, C. L. (2019) · Alzheimer s Research & Therapy · doi:10.1186/s13195-019-0497-9 · Cited by 73
Neem Derivatives Inhibits Tau Aggregation
Gorantla, N. V., Das, R. R., Mulani, F. A., Thulasiram, H. V., & Chinnathambi, S. (2019) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190118 · Cited by 69
Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer’s Disease
Hameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 69
Biosensors Integration in Blood–Brain Barrier-on-a-Chip: Emerging Platform for Monitoring Neurodegenerative Diseases
Mir, M., Palma-Florez, S., Lagunas, A., Lopez-Martinez, M. J., & Samitier, J. (2022) · ACS Sensors · doi:10.1021/acssensors.2c00333 · Cited by 67
The leukotriene signaling pathway: a druggable target in Alzheimer’s disease
Michael, J., Marschallinger, J., & Aigner, L. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.09.008 · Cited by 70
Improvements of symptoms of Alzheimer`s disease by inhibition of the angiotensin system
Quitterer, U., & AbdAlla, S. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.014 · Cited by 67
The cholinergic system in subtypes of Alzheimer’s disease: an in vivo longitudinal MRI study
Machado, A., Ferreira, D., Grothe, M. J., Eyjolfsdottir, H., Almqvist, P. M., Cavallin, L., Lind, G., Lind, G., Seiger, Å., Teipel, S., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00620-7 · Cited by 65
Early prevention of cognitive impairment in the community population: The Beijing Aging Brain Rejuvenation Initiative
Yang, C., Li, X., Zhang, J., Chen, Y., Li, H., Wei, D., Lü, P., Liang, Y., Liu, Z., Shu, N., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12326 · Cited by 64
Sequences of cognitive decline in typical Alzheimer's disease and posterior cortical atrophy estimated using a novel event‐based model of disease progression
Firth, N. C., Primativo, S., Brotherhood, E., Young, A. L., Yong, K. X. X., Crutch, S. J., Alexander, D. C., & Oxtoby, N. P. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12083 · Cited by 65
The Role of Everyday Sounds in Advanced Dementia Care
Houben, M., Brankaert, R., Bakker, S., Kenning, G., Bongers, I. M. B., & Eggen, B. H. (2020) · CHI Conference on Human Factors in Computing Systems · doi:10.1145/3313831.3376577 · Cited by 63
Dietary Regulation of Gut-Brain Axis in Alzheimer’s Disease: Importance of Microbiota Metabolites
Frausto, D. M., Forsyth, C. B., Keshavarzian, A., & Voigt, R. M. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.736814 · Cited by 61
Management of Dementia-Related Psychosis, Agitation and Aggression: A Review of the Pharmacology and Clinical Effects of Potential Drug Candidates
Marcinkowska, M., Śniecikowska, J., Fajkis-Zajączkowska, N., Paśko, P., Franczyk, W., & Kołaczkowski, M. (2020) · CNS Drugs · doi:10.1007/s40263-020-00707-7 · Cited by 65
Tau Filament Self-Assembly and Structure: Tau as a Therapeutic Target
Oakley, S. S., Maina, M. B., Marshall, K. E., Al‐Hilaly, Y. K., Harrington, C., Wischik, C. M., & Serpell, L. C. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2020.590754 · Cited by 59
Aducanumab: The first targeted Alzheimer's therapy
Yang, P., & Sun, F. (2021) · Drug Discoveries & Therapeutics · doi:10.5582/ddt.2021.01061 · Cited by 62
N-alkylpiperidine carbamates as potential anti-Alzheimer’s agents
Košak, U., Strašek, N., Knez, D., Jukič, M., Žakelj, S., Zahirović, A., Pišlar, A. H., Brazzolotto, X., Nachon, F., Kos, J., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112282 · Cited by 61
Challenges and opportunities for improving the landscape for Lewy body dementia clinical trials
Goldman, J. G., Forsberg, L. K., Boeve, B. F., Armstrong, M. J., Irwin, D. J., Ferman, T. J., Galasko, D. R., Galvin, J. E., Kaufer, D., Leverenz, J. B., et al. (2020) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00703-5 · Cited by 62
Exploring the multifunctional role of melatonin in regulating autophagy and sleep to mitigate Alzheimer’s disease neuropathology
Hossain, M. F., Wang, N., Chen, R., Li, S., Roy, J., Uddin, M. G., Li, Z., Lim, L. W., & Song, Y. (2021) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101304 · Cited by 62
Neuropharmacology of the Neuropsychiatric Symptoms of Dementia and Role of Pain: Essential Oil of Bergamot as a Novel Therapeutic Approach
Scuteri, D., Rombolà, L., Morrone, L. A., Bagetta, G., Sakurada, S., Sakurada, T., Tonin, P., & Corasaniti, M. T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20133327 · Cited by 60
The Alzheimer's Prevention Registry: A Large Internet-Based Participant Recruitment Registry to Accelerate Referrals to Alzheimer's-Focused Studies
Langbaum, J. B., High, N. M., Nichols, J. B., Kettenhoven, C. L., Reiman, E. M., & Tariot, P. N. (2020) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2020.31 · Cited by 60
Ghrelin in Alzheimer’s disease: Pathologic roles and therapeutic implications
Jeon, S. G., Hong, S. B., Nam, Y., Tae, J., Yoo, A., Song, E. J., Kim, K. I., Lee, D., Park, J., Lee, S. M., et al. (2019) · Ageing Research Reviews · doi:10.1016/j.arr.2019.100945 · Cited by 60
New 3d multifunctional metal chelates of sulfonamide: Spectral, vibrational, molecular modeling, DFT, medicinal and in silico studies
Hassan, A. U., Sumrra, S. H., Imran, M., & CHOHAN, Z. H. (2022) · Journal of Molecular Structure · doi:10.1016/j.molstruc.2021.132305 · Cited by 56
GeneMatch: A novel recruitment registry using at‐home APOE genotyping to enhance referrals to Alzheimer's prevention studies
Langbaum, J. B. S., Karlawish, J. H., Roberts, J. S., Wood, E. M., Bradbury, A. R., High, N. M., Walsh, T. L., Gordon, D., Aggarwal, R., Davis, P., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.12.007 · Cited by 57
Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease
Ghosh, S., Durgvanshi, S., Agarwal, S., Raghunath, M., & Sinha, J. K. (2020) · Current Neuropharmacology · doi:10.2174/1570159x18666200429011823 · Cited by 57
Mechanistic insights and emerging therapeutic stratagems for Alzheimer’s disease
Rajendran, K., & Krishnan, U. M. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102309 · Cited by 59
Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer
Branigan, G. L., Soto, M., Neumayer, L. A., Rodgers, K. E., & Brinton, R. D. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.1541 · Cited by 57
In silico molecular studies of natural compounds as possible anti-Alzheimer’s agents: ligand-based design
Iwaloye, O., Elekofehinti, O. O., Momoh, A. I., Kikiowo, B., & Ariyo, E. O. (2020) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-020-00262-7 · Cited by 55
Molecular mechanisms in Alzheimer's disease and the impact of physical exercise with advancements in therapeutic approaches
Siddappaji, K. K., & Gopal, S. (2021) · AIMS neuroscience · doi:10.3934/neuroscience.2021020 · Cited by 58
M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa, M., Hesse, S., & Bradley, S. J. (2020) · Advances in pharmacology · doi:10.1016/bs.apha.2019.12.003 · Cited by 55
Targeting increased levels of APP in Down syndrome: Posiphen‐mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model
Chen, X., Salehi, A., Pearn, M. L., Overk, C., Nguyen, P. D., Kleschevnikov, A. M., Maccecchini, M. L., & Mobley, W. C. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12185 · Cited by 55
Impact of increased APP gene dose in Down syndrome and the Dp16 mouse model
Sawa, M., Overk, C., Becker, A., Derse, D., Albay, R., Weldy, K., Salehi, A., Beach, T. G., Doran, E., Head, E., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12463 · Cited by 54
Harnessing the power of bee venom for therapeutic and regenerative medical applications: an updated review
Sadek, K. M., Shib, N. A., Taher, E. S., Rashed, F., Shukry, M., Atia, G. A. N., Taymour, N., El-Nablaway, M., Ibrahim, A. M., Ramadan, M. M., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1412245 · Cited by 54
Intrinsic connectivity of the human brain provides scaffold for tau aggregation in clinical variants of Alzheimer’s disease
Therriault, J., Pascoal, T. A., Savard, M., Mathotaarachchi, S. S., Benedet, A. L., Chamoun, M., Tissot, C., Lussier, F. Z., Rahmouni, N., Stevenson, J., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8693 · Cited by 58
Biomarkers for Alzheimer’s disease beyond amyloid and tau
Zetterberg, H., & Schott, J. M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0348-z · Cited by 53
Network pharmacology-based strategy to investigate pharmacological mechanisms of Tinospora sinensis for treatment of Alzheimer's disease
Zhou, F., He, K., Yang, G., Yang, X., Chen, Y., Sun, M.-S., Qiu, X., Yan, F., Huang, H., Yao, L., et al. (2020) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2020.112940 · Cited by 52
Bacterial Extracellular DNA Promotes β-Amyloid Aggregation
Tetz, G. V., & Tetz, V. (2021) · Microorganisms · doi:10.3390/microorganisms9061301 · Cited by 50
Qß Virus-like particle-based vaccine induces robust immunity and protects against tauopathy
Maphis, N. M., Peabody, J., Crossey, E., Jiang, S., Ahmad, F. A. J., Álvarez, M. J., Mansoor, S. K., Yaney, A., Yang, Y., Sillerud, L. O., et al. (2019) · npj Vaccines · doi:10.1038/s41541-019-0118-4 · Cited by 48
BAD-mediated neuronal apoptosis and neuroinflammation contribute to Alzheimer's disease pathology
Zhang, L., Qian, Y., Li, J., Zhou, X., Xu, H. J., Yan, J., Xiang, J., Yuan, X., Sun, B., Sisodia, S. S., et al. (2021) · iScience · doi:10.1016/j.isci.2021.102942 · Cited by 54
Future avenues for Alzheimer's disease detection and therapy: liquid biopsy, intracellular signaling modulation, systems pharmacology drug discovery
Hampel, H. J., Vergallo, A., Caraci, F., Cuello, A. C., Lemercier, P., Vellas, B. J., Giudici, K. V., Baldacci, F., Hänisch, B., Haberkamp, M., et al. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108081 · Cited by 52
A Review of the Recent Advances in Alzheimer’s Disease Research and the Utilization of Network Biology Approaches for Prioritizing Diagnostics and Therapeutics
Hajjo, R., Sabbah, D. A., Abusara, O. H., & Bawab, A. Q. A. (2022) · Diagnostics · doi:10.3390/diagnostics12122975 · Cited by 57
Catalytic Nanoparticles in Biomedical Applications: Exploiting Advanced Nanozymes for Therapeutics and Diagnostics
Manoharan, D., Wang, L., Chen, Y., Li, W., & Yeh, C. (2024) · Advanced Healthcare Materials · doi:10.1002/adhm.202400746 · Cited by 50
The effects of bioactive components from the rhizome of Salvia miltiorrhiza (Danshen) on the characteristics of Alzheimer’s disease
Chong, C., Su, H., Lu, J., & Wang, Y. (2019) · Chinese Medicine · doi:10.1186/s13020-019-0242-0 · Cited by 52
Alzheimer's Prevention Initiative Generation Program: Development of an APOE genetic counseling and disclosure process in the context of clinical trials
Langlois, C. M., Bradbury, A. R., Wood, E. M., Roberts, J. S., Kim, S. Y. H., Riviere, M., Liu, F., Reiman, E. M., Tariot, P. N., Karlawish, J. H., et al. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2019.09.013 · Cited by 50
The Post-amyloid Era in Alzheimer's Disease: Trust Your Gut Feeling
Osorio, C. P., Kanukuntla, T., Diaz, E. L., Jafri, N., Cummings, M., & Sfera, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00143 · Cited by 50
Upregulation of Ca2+-binding proteins contributes to VTA dopamine neuron survival in the early phases of Alzheimer’s disease in Tg2576 mice
Barbera, L. L., Nobili, A., Cauzzi, E., Paoletti, I., Federici, M., Saba, L., Giacomet, C., Marino, R., Krashia, P., Melone, M., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00580-6 · Cited by 49
Genetic and multi‐omic risk assessment of Alzheimer's disease implicates core associated biological domains
Cary, G. A., Wiley, J. C., Gockley, J., Keegan, S., Amirtha Ganesh, S. S., Heath, L., Butler, R. R., Mangravite, L. M., Logsdon, B. A., Longo, F. M., et al. (2024) · Alzheimer's & Dementia: Translational Research & Clinical Interventions · doi:10.1002/trc2.12461 · Cited by 49
Key Peptides and Proteins in Alzheimer’s Disease
Penke, B., Bogár, F., Paragi, G., Gera, J., & Fülöp, L. (2019) · Current Protein and Peptide Science · doi:10.2174/1389203720666190103123434 · Cited by 51
A Clinical Trial of Transcranial Electromagnetic Treatment in Alzheimer’s Disease: Cognitive Enhancement and Associated Changes in Cerebrospinal Fluid, Blood, and Brain Imaging
Arendash, G. W., Cao, C., Abulaban, H., Baranowski, R., Wisniewski, G., Becerra, L. R., Andel, R., Lin, X., Zhang, X., Wittwer, D., et al. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-190367 · Cited by 52
Tau Aggregation Inhibiting Peptides as Potential Therapeutics for Alzheimer Disease
Aillaud, I., & Funke, S. A. (2022) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-022-01230-7 · Cited by 51
Machine Learning for Discovery of GSK3β Inhibitors
Vignaux, P. A., Minerali, E., Foil, D. H., Puhl, A. C., & Ekins, S. (2020) · ACS Omega · doi:10.1021/acsomega.0c03302 · Cited by 49
Polyamine biomarkers as indicators of human disease
Amin, M., Tang, S., Shalamanova, L., Taylor, R. L., Wylie, S. R., Abdullah, B. M., & Whitehead, K. A. (2021) · Biomarkers · doi:10.1080/1354750x.2021.1875506 · Cited by 51
An evaluation of lumateperone tosylate for the treatment of schizophrenia
Vyas, P., Hwang, B. J., & Brašić, J. R. (2019) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2019.1695778 · Cited by 47
Evaluation of Activity of Some 2,5-Disubstituted Benzoxazole Derivatives against Acetylcholinesterase, Butyrylcholinesterase and Tyrosinase: ADME Prediction, DFT and Comparative Molecular Docking Studies
Çeli̇k, İ., Erol, M., Temiz‐Arpacı, Ö., Şenol, F. S., & Orhan, İ. E. (2020) · Polycyclic aromatic compounds · doi:10.1080/10406638.2020.1737827 · Cited by 47
Contribution of Alzheimer's biomarkers and risk factors to cognitive impairment and decline across the Alzheimer's disease continuum
Tosun, D., Demir, Z., Veitch, D. P., Weintraub, D. A., Aisen, P. S. S., Jack, C. R., Jagust, W., Petersen, R. C., Saykin, A. J., Shaw, L. M. J., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12480 · Cited by 46
Novel chromanone-dithiocarbamate hybrids as multifunctional AChE inhibitors with β-amyloid anti-aggregation properties for the treatment of Alzheimer’s disease
Jiang, N., Ding, J., Liu, J., Sun, X., Zhang, Z., Mo, Z., Li, X., Yin, H. Z., Tang, W., & Xie, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.103027 · Cited by 46
Advances in amyloid beta oligomer detection applications in Alzheimer's disease
Jamerlan, A., An, S. S. A., & Hulme, J. (2020) · TrAC Trends in Analytical Chemistry · doi:10.1016/j.trac.2020.115919 · Cited by 46
Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers
Koychev, I. G., Hofer, M., & FRIEDMAN, N. C. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230458 · Cited by 52
An insight into the in vivo imaging potential of curcumin analogues as fluorescence probes
Liu, Y., Zhang, C., Pan, H., Li, L., Yu, Y., & Liu, B. (2020) · Asian Journal of Pharmaceutical Sciences · doi:10.1016/j.ajps.2020.11.003 · Cited by 47
Taking Advantage of the Selectivity of Histone Deacetylases and Phosphodiesterase Inhibitors to Design Better Therapeutic Strategies to Treat Alzheimer’s Disease
Cuadrado‐Tejedor, M., Pérez-González, M., García‐Muñoz, C., Muruzabal, D., García, C., Rabal, O., Segura, V., Sánchez-Arias, J. A., Oyarzábal, J., & García‐Osta, A. (2019) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2019.00149 · Cited by 45
5-HT6 receptor agonist and antagonist improve memory impairments and hippocampal BDNF signaling alterations induced by MK-801
Rychtyk, J., Partyka, A., Gdula‐Argasińska, J., Mysłowska, K., Wilczyńska-Zawal, N., Jastrzębska‐Więsek, M., & Wesołowska, A. (2019) · Brain Research · doi:10.1016/j.brainres.2019.146375 · Cited by 45
Clinical drug development for dementia with Lewy bodies: past and present
Lee, G., Cummings, J. L., Decourt, B., Leverenz, J. B., & Sabbagh, M. N. (2019) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1681398 · Cited by 46
Self-citation
Design, synthesis and evaluation of novel dimethylamino chalcone-O-alkylamines derivatives as potential multifunctional agents against Alzheimer’s disease
Sang, Z., Song, Q., Cao, Z., Deng, Y., Tan, Z., & Zhang, L. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113310 · Cited by 46
Integrated miRNA-Seq and mRNA-Seq Study to Identify miRNAs Associated With Alzheimer’s Disease Using Post-mortem Brain Tissue Samples
Li, Q. S., & Cai, D. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.620899 · Cited by 45
Meta-analysis of the human brain transcriptome identifies heterogeneity across human AD coexpression modules robust to sample collection and methodological approachPreprint
Logsdon, B. A., Perumal, T. M., Swarup, V., Wang, M., Funk, C. C., Gaiteri, C., Allen, M., Wang, X., Dammer, E. B., Srivastava, G. P., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/510420 · Cited by 46
Therapeutic Targeting of Casein Kinase 1δ/ε in an Alzheimer’s Disease Mouse Model
Adler, P., Mayne, J., Walker, K., Ning, Z., & Figeys, D. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00312 · Cited by 45
β-amyloid and Oxidative Stress: Perspectives in Drug Development
Caruso, G., Spampinato, S. F., Cardaci, V., Caraci, F., Sortino, M. A., & Merlo, S. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666191209115431 · Cited by 45
Drug Repositioning for Alzheimer’s Disease: Finding Hidden Clues in Old Drugs
Ihara, M., & Saitô, S. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-200049 · Cited by 45
Application of optogenetic Amyloid-β distinguishes between metabolic and physical damages in neurodegeneration
Lim, C. H., Kaur, P., Teo, E., Lam, V. Y. M., Zhu, F., Kibat, C., Gruber, J., Mathuru, A. S., & Tolwinski, N. S. (2020) · eLife · doi:10.7554/elife.52589 · Cited by 44
Sulfur-containing therapeutics in the treatment of Alzheimer’s disease
Zhu, H., Dronamraju, V., Xie, W., & More, S. S. (2021) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02687-1 · Cited by 46
Cognitive Reserve, Leisure Activity, and Neuropsychological Profile in the Early Stage of Cognitive Decline
Lee, S. Y., Kang, J. M., Kim, D. J., Woo, S. K., Lee, J., & Cho, S. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.590607 · Cited by 44

Authors: Cummings, J., Lee, G., Ritter, A., & Zhong, K.
Affiliations: Cleveland Clinic (US)
Global Alzheimer's Platform Foundation (US)
Corresponding author: Cummings, Jeffrey
ORCID: Cummings, Jeffrey
Lee, Garam
Zhong, Kate
Venue: Alzheimer's & Dementia: Translational Research & Clinical Interventions
Publisher: Wiley
Published: 2018-01
Volume: 4
Issue: 1
Pages: 195-214
ISSN: 2352-8737 (ISSN-L)
DOI: 10.1016/j.trci.2018.03.009
PMC: PMC6021548
OpenAlex: W2918066696
Cited by: 697
References: 48
Citations by year: 2026: 19 · 2025: 28 · 2024: 39 · 2023: 22 · 2022: 55 · 2021: 138 · 2020: 177 · 2019: 170 · 2018: 42
FWCI: 91.11
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by-nc-nd
creativecommons.org/licenses/by-nc-nd/4.0/ (vor, 122 d)
Locations: Alzheimer s & Dementia Translational Research & Clinical Interventions (publishedVersion, cc-by-nc-nd)
Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
PubMed Central (publishedVersion, cc-by-nc-nd)
PubMed (publishedVersion)
Funders: National Institute of General Medical Sciences (P20GM109025)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Keywords: Alzheimer's disease, drug development pipeline, clinical trials, disease-modifying therapy, amyloid biomarkers, prodromal Alzheimer's disease, preclinical Alzheimer's disease, neuropsychiatric symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Alzheimer's disease drug development pipeline: 2018

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks